NXP 74HCT125PW 4-CH Non-Inverting 3-ST CMOS 14-Pin TSSOP New Lot Quantity-100 Other Integrated Circuits


  1. Home
  2. NXP 74HCT125PW 4-CH Non-Inverting 3-ST CMOS 14-Pin TSSOP New Lot Quantity-100
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
NXP 74HCT125PW 4-CH Non-Inverting 3-ST CMOS 14-Pin TSSOP New Lot Quantity-100
Condition: New: A brand-new, unused, unopened, undamaged item in its original packaging (where packaging is Brand:

NXP

MPN:

74HCT125PW

UPC:

Does Not Apply

Country/Region of Manufacture: Unknown Model:

74HCT125PW

published on tue nov 09 2021

NXP 74HCT125PW 4-CH Non-Inverting 3-ST CMOS 14-Pin TSSOP New Lot Quantity-100 Other Integrated Circuits

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

NXP 74HCT125PW 4-CH Non-Inverting 3-ST CMOS 14-Pin TSSOP New Lot Quantity-100 Other Integrated Circuits

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS